<DOC>
	<DOC>NCT00812357</DOC>
	<brief_summary>Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma</brief_summary>
	<brief_title>Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Asthmatic patients treated for this disease with Symbicort Turbuhaler Patients monitored for asthma by the doctor for at least 12 months Patients seen in outpatient care at the baseline visit Patients agreeing to participate in the study Patients with any chronic lower respiratory disease other than asthma Patients receiving antiIgE agents in the last 4 months Patients receiving desensitisation treatment outside of the maintenance phase Patients deemed to be unable to respond to the study for linguistic or cognitive reasons</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Symbicort Turbuhaler</keyword>
	<keyword>asthma</keyword>
	<keyword>cohort study</keyword>
	<keyword>France</keyword>
</DOC>